BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32007298)

  • 1. Experience of using hemodialysis with medium cut-off dialyzer in cast nephropathy.
    Cazorla López JM; García García-Doncel A; Naranjo Muñoz J; Villanego Fernández F; Vigara Sánchez LA; Ceballos Guerrero M
    Nefrologia (Engl Ed); 2020; 40(3):367-369. PubMed ID: 32007298
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical Trial.
    Bridoux F; Carron PL; Pegourie B; Alamartine E; Augeul-Meunier K; Karras A; Joly B; Peraldi MN; Arnulf B; Vigneau C; Lamy T; Wynckel A; Kolb B; Royer B; Rabot N; Benboubker L; Combe C; Jaccard A; Moulin B; Knebelmann B; Chevret S; Fermand JP;
    JAMA; 2017 Dec; 318(21):2099-2110. PubMed ID: 29209721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure.
    Pendón-Ruiz de Mier MV; Alvarez-Lara MA; Ojeda-López R; Martín-Malo A; Carracedo J; Caballero-Villarraso J; Alonso C; Aljama P
    Nefrologia; 2013 Nov; 33(6):788-96. PubMed ID: 24241366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
    Martín-Gómez MA; García-Marcos SA; Caba-Molina M; Palacios-Gómez ME; Gómez-Morales M; Claver-Ferré C
    Nefrologia; 2013 Nov; 33(6):862-4. PubMed ID: 24241381
    [No Abstract]   [Full Text] [Related]  

  • 5. Recovery of kidney function following delayed use of Theralite™ dialyzer in a patient with myeloma cast nephropathy.
    Dahal K; Shastri S; Narayanasami U; Bijol V; Rider K; Strom JA; Jaber BL
    Clin Nephrol; 2013 Apr; 79(4):318-22. PubMed ID: 22541683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
    Sens F; Chaintreuil D; Jolivot A; Guebre-Egziabher F; Robinson P; Karlin L; Bridoux F; Juillard L
    Am J Nephrol; 2017; 46(5):355-363. PubMed ID: 29017155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thirteen treated of acute renal failure secondary to multiple myeloma with high cut off filters.
    Berni Wennekers A; Martín Azara MP; Dourdil Sahun V; Bergasa Liberal B; Ruiz Laiglesia JE; Vernet Perna P; Alvarez Lipe R
    Nefrologia; 2016; 36(4):418-26. PubMed ID: 27255910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.
    Sinisalo M; Silvennoinen R; Wirta O
    Am J Hematol; 2012 Jun; 87(6):640. PubMed ID: 22473521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bence-Jones Protein λ-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Long-term Bortezomib and Dexamethasone Therapy.
    Yamaguchi W; Yui N; Nagao T; Oshikawa G; Negi M; Iimori S; Okado T; Rai T; Uchida S
    Intern Med; 2016; 55(3):263-8. PubMed ID: 26831021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy.
    Rousseau-Gagnon M; Agharazii M; De Serres SA; Desmeules S
    PLoS One; 2015; 10(10):e0140463. PubMed ID: 26466100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
    Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
    Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy.
    Ward F; Dunne O; Crotty TB; Fennelly D; Watson A; Holian J
    Ir Med J; 2012 May; 105(5):148-9. PubMed ID: 22803494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients.
    Pendón-Ruiz de Mier MV; Ojeda R; Álvarez-Lara MA; Navas A; Alonso C; Caballero-Villarraso J; Aljama P; Álvarez MA; Soriano S; Rodríguez M; Martín-Malo A
    BMC Nephrol; 2020 Jun; 21(1):227. PubMed ID: 32539688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early use of PEPA dialyzer for light chains removal and for the recovery from myeloma cast nephropathy: A case report.
    Donati G; Zappulo F; Croci Chiocchini AL; Comai G; Zamagni E; La Manna G
    Hemodial Int; 2019 Jul; 23(3):E97-E99. PubMed ID: 30791209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective Removal of κ-Free Light Chains with Hemodialysis Using Fresenius Ultraflux® EMiC®2 Dialyser in a Patient with Myeloma Cast Nephropathy, with Associated Cost Savings.
    Jayaballa M; Bose B; Gangadharan Komala M; Fischer ER; Taper J; Sud K
    Blood Purif; 2016; 42(2):158-9. PubMed ID: 27270690
    [No Abstract]   [Full Text] [Related]  

  • 16. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
    Cockwell P; Cook M
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple myeloma, severe hypercalcaemia, acute renal failure and multiple organ failure due to calcinosis].
    Martínez Mateu JG; Losada González GP; Munar Vila MA; Uriol Rivera M; Gómez Marqués G; Tugores AC
    Nefrologia; 2011; 31(2):233-4. PubMed ID: 21461024
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
    Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
    Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin A nephropathy in a patient with IgG kappa light-chain myeloma.
    Chandra A; Kaul A; Aggarwal V
    Saudi J Kidney Dis Transpl; 2017; 28(4):937-941. PubMed ID: 28748903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary renal allograft dysfunction.
    Foster K; Cohen DJ; D'Agati VD; Markowitz GS
    Am J Kidney Dis; 2004 Aug; 44(2):376-81. PubMed ID: 15264198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.